Your browser doesn't support javascript.
loading
Unlocking the Therapeutic Symphony: A Systematic Review Exploring the Role of Levosimendan in the Management of Heart Failure.
Ali, Rahmat; Sajjad, Waseem; Mushtaq, Iqra; Farooqi, Humaira; Sohail, Amir; Wazir Khan, Hamza; Tabasum, Pakeezah; Haseeb, Abdul; Ismail, Wajahat Ullah.
Afiliación
  • Ali R; Department of Medicine, Mayo Hospital, Lahore, PAK.
  • Sajjad W; Department of Medicine, Mayo Hospital, Lahore, PAK.
  • Mushtaq I; Department of Cardiology, Guy's and St Thomas' NHS Foundation Trust, London, GBR.
  • Farooqi H; Department of Pathology, Mayo Hospital, Lahore, PAK.
  • Sohail A; Department of Medicine, Mayo Hospital, Lahore, PAK.
  • Wazir Khan H; Department of Medicine, Mayo Hospital, Lahore, PAK.
  • Tabasum P; Department of Medicine, Peoples University of Medical and Health Sciences for Women, Nawabshah, PAK.
  • Haseeb A; Department of Medicine, Mayo Hospital, Lahore, PAK.
  • Ismail WU; Department of Medicine, Mayo Hospital, Lahore, PAK.
Cureus ; 16(6): e62799, 2024 Jun.
Article en En | MEDLINE | ID: mdl-39036117
ABSTRACT
Levosimendan, a novel drug, a calcium-sensitizing inotrope, has emerged as a potential therapeutic modulator for heart failure (HF). This review appraises the efficacy and safety of levosimendan in managing HF, in different clinical settings. The study aims to examine the clinical outcomes reported in the selected trials to determine the effectiveness of levosimendan in improving key parameters related to HF. Seven relevant studies encompassing 1200 participants were identified from three databases. Inclusion criteria included clinical trials that investigated the therapeutic efficacy of levosimendan in the treatment of HF, and studies involving both adult and pediatric participants. Exclusion criteria involved studies with insufficient data, studies other than clinical trials, case reports, letters to the editor, conference papers, grey literature, and studies published in a language other than English. Upon evaluating the included studies, it was found that levosimendan shows improved hemodynamics and clinical efficacy in patients with severe septic cardiomyopathy. Levosimendan enhanced right ventricular (RV) function in patients with RV dysfunction after mitral valve (MV) surgeries and decreased the amount of N-terminal pro-B-type natriuretic peptide (NT-ProBNP) in non-ST elevated myocardial infarction (NSTEMI) patients with elevated NT-proBNP, all without increasing the overall cost or duration of hospitalization. Despite variations in study designs and participant characteristics, evidence suggests levosimendan significantly improves left ventricular ejection fraction (LVEF) and exercise tolerance measured by a six-minute walk distance. Notably, its safety profile appears favorable with minimal arrhythmic events and comparable rates of adverse effects to a placebo. This systematic review highlights levosimendan's promising potential for HF management, warranting further research to solidify its clinical role.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2024 Tipo del documento: Article